$20.31
0.32% today
Nasdaq, Feb 28, 05:20 pm CET
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

IDEAYA Biosciences Inc Stock price

$20.24
-3.56 14.96% 1M
-19.11 48.56% 6M
-5.46 21.25% YTD
-25.17 55.43% 1Y
+7.04 53.33% 3Y
+13.27 190.39% 5Y
+9.05 80.88% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.51 2.46%
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

Key metrics

Market capitalization $1.77b
Enterprise Value $1.11b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 159.23
P/S ratio (TTM) P/S ratio 253.11
P/B ratio (TTM) P/B ratio 1.65
Revenue growth (TTM) Revenue growth -70.07%
Revenue (TTM) Revenue $7.00m
EBIT (operating result TTM) EBIT $-326.98m
Free Cash Flow (TTM) Free Cash Flow $-251.44m
Cash position $676.32m
EPS (TTM) EPS $-3.30
P/E forward negative
P/S forward 128.22
EV/Sales forward 80.66
Short interest 12.36%
Show more

Is IDEAYA Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

IDEAYA Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a IDEAYA Biosciences Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a IDEAYA Biosciences Inc forecast:

Buy
93%
Hold
7%

Financial data from IDEAYA Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
7 7
70% 70%
100%
- Direct Costs 3.83 3.83
4% 4%
55%
3.17 3.17
84% 84%
45%
- Selling and Administrative Expenses 32 32
55% 55%
452%
- Research and Development Expense 295 295
128% 128%
4,210%
-323 -323
148% 148%
-4,616%
- Depreciation and Amortization 3.83 3.83
4% 4%
55%
EBIT (Operating Income) EBIT -327 -327
143% 143%
-4,671%
Net Profit -274 -274
143% 143%
-3,921%

In millions USD.

Don't miss a Thing! We will send you all news about IDEAYA Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEAYA Biosciences Inc Stock News

Neutral
PRNewsWire
about 6 hours ago
SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on February 27, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 125,600 shares of the C...
Neutral
PRNewsWire
15 days ago
Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled in neoadjuvant UM trial and targeting clinical data and regulatory update(s) in H1 2025, including vision data in plaque brachytherapy patients Targeting median OS readout in ~40 1L MUM patients in 2025 Targeting expansion of study ...
Neutral
PRNewsWire
15 days ago
Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in MTAP-deletion NSCLC The potential first-in-class clinical combination of IDE397 and Trodelvy targets two mechanistically distinct and complementary nodes of MTAP-deletion in solid tumors MTAP-deletio...
More IDEAYA Biosciences Inc News

Company Profile

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Yujiro Hata
Employees 131
Founded 2015
Website www.ideayabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today